FK506 controls CD40L-induced systemic autoimmunity in mice

Journal of Investigative Dermatology

Volumn 126, Issue 6, 2006, Pages 1307-1315

  Loser, Karin ^a   Balkow, Sandra ^a   Higuchi, Tetsuya ^a   Apelt, Jenny ^a   Kuhn, Annegret ^b   Luger, Thomas A ^a   Beissert, Stefan ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CALCINEURIN INHIBITOR; CD40 ANTIGEN; CD40 LIGAND; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2; TACROLIMUS; CALCINEURIN; IMMUNOSUPPRESSIVE AGENT;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CERVICAL LYMPH NODE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DERMATITIS; FEMALE; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; KIDNEY FUNCTION; LEUKOCYTE; LYMPHADENOPATHY; MACROPHAGE; MIXED CONNECTIVE TISSUE DISEASE; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; ANIMAL; BLOOD; CELL NUCLEUS; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CALCINEURIN; CD40 LIGAND; CELL NUCLEUS; DERMATITIS; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; TACROLIMUS;

EID: 33745519519     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700185     Document Type: Article

References (49)

1. Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM (1996) Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 50:1110-7
2. Bigby M (2005) Pimecrolimus and tacrolimus for the treatment of intertriginous and facial psoriasis: are they effective? Arch Dermatol 141:1152-3
3. Canadas O, Guerrero R, Garcia-Canero R, Orellana G, Menendez M, Casals C (2004) Characterization of liposomal tacrolimus in lung surfactant-like phospholipids and evaluation of its immunosuppressive activity. Biochemistry 43:9926-38
4. Clardy J (1995) The chemistry of signal transduction. Proc Natl Acad Sci USA 92:56-61
5. Cron RQ (2003) CD154 transcriptional regulation in primary human CD4T cells. Immunol Res 27:185-202
6. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK (1996) Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97:2063-73
7. Draelos Z, Nayak A, Pariser D, Shupack JL, Chon K, Abrams B et al. (2005) Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 53:602-9
8. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH (1990) Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 144:251-8
9. Eckardt A, Starke O, Stadler M, Reuter C, Hertenstein B (2004) Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 40:811-4
10. Elad S, Or R, Resnick I, Shapira MY (2003) Topical tacrolimus - a novel treatment alternative for cutaneous chronic graft-versus-host-disease. Transpl Int 16:665-70
11. Fields ML, Nish SA, Hondowicz BD, Metzgar MH, Wharton GN, Caton AJ et al. (2005) The influence of effector T cells and Fas ligand on lupus-associated B cells. J Immunol 175:104-11
12. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C et al. (2003) Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 112:1506-20
13. Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger A (2004) Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 51:52-61
14. Gunzer M, Weishaupt C, Flanelles L, Grabbe S (2001) Two-step negative enrichment of CD4+ and CD8+ T cells from murine spleen via nylon wool adherence and an optimized antibody cocktail. J Immunol Methods 258:55-63
15. Ikezumi Y, Kanno K, Koike H, Tomita M, Uchiyama M, Shimizu F et al. (2002) FK506 ameliorates proteinuria and glomerular lesions induced by anti Thy1.1 monoclonal antibody 1-22-3. Kidney Int 61:1339-50
16. Katsiari CG, Liossis SN, Souliotis VL, Dimopoulos AM, Manoussakis MN, Sfikakis PP (2002) Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol 103:54-62
17. Keicho N, Sawada S, Kitamura K, Yotsumoto H, Takaku F (1991) Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. Cell Immunol 132:285-94
18. Kino T, Hatanaka H, Hashimoto M, Nishiyama H, Goto T, Okuahara M et al. (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces I. Fermentation, isolation and physico-chemical and biological characteristics. J Antibiot (Tokyo) 40:1249-55
19. Koshy M, Berger D, Crow MK (1996) Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98:826-37
20. Lan CC, Chen GS, Chiou MH, Wu CS, Chang CH, Yu HS (2005) FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 153:498-505
21. Lan CC, Kao YH, Huang SM, Yu HS, Chen GS (2004) FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin. Br J Dermatol 151:679-84
22. Lebwohl M, Freeman A, Chapman MS, Feldman S, Hartle J, Henning A (2005) Proven efficacy of tacrolimus for facial and intertriginous psoriasis. Arch Dermatol 141:1154
23. Loser K, Hansen W, Apelt J, Balkow S, Buer J, Beissert S (2005) In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity. Gene Therapy 12:1294-304
24. Marie JC, Letterio JJ, Gavin M, Rudensky AJ (2005) TGF-beta 1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201:1061-7
25. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B et al. (1997) Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64:436-43
26. McCauley J, Shapiro R, Ellis D, Igdal H, Tzakis A, Starzl TE (1993a) Pilot trial of FK506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 8:1286-90
27. McCauley J, Shapiro R, Woods H, Scantlebury V, Irish W, McMichael J et al. (1993b) Renal transplantation under FK506 in African-Americans: early experience. Transplant Proc 25:2468-9
28. Mehling A, Loser K, Varga G, Metze D, Luger TA, Schwarz T et al. (2001) Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med 194:615-28
29. Mellergard J, Havarinasab S, Hultman P (2004) Short- and long-term effects of T-cell modulating agents in experimental autoimmunity. Toxicology 196:197-209
30. Minoda M, Ohno M, Tomioka Y, Hamada K, Yamazoe Y, Higashikawa M et al. (1992) Effects of gamma-interferon and FK506 on resting B cell proliferation of New Zealand black/white F1 mice. Microbiol Immunol 36:885-94
31. Muraoka K, Fujimoto K, Sun X, Yoshioka K, Shimizu K, Yagi M et al. (1996) Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kapa (B). Implications for FK506 nephropathy. J Clin Invest 97:2433-9
32. Nakahama H, Obata K, Matsuyama T, Sugita M, Horio M, Oka K et al. (1999a) Effect of a novel Immunosuppressant, FK506, on autoimmune glomerulonephritis in Brown Norway rats. Nephron 81:215-20
33. Nakahama H, Obata K, Sugita M, Horio M, Oka K, Moriyama T (1999b) Effect of FK506 in the treatment of autoimmune glomerulonephritis in Brown Norway rats. Nephron 81:421-7
34. Olivier V, Lacour JP, Mousnier A, Garraffo R, Monteil RA, Ortonne JP (2002) Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. Arch Dermatol 138:1335-8
35. Ongenae K, Van Geel N, Naeyaert JM (2003) Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 16:90-100
36. Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A et al. (1994) Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 58:170-8
37. Reitamo S, Ortonne JP, Sand C, Cambazardt F, Bieber I, Fölster-Holst R et al. (2005) European Tacrolimus Ointment Study Group: a multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 152:1282-9
38. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD et al. (1997) A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study. N Engl J Med 337:816-21
39. Sakr MF, McClain CJ, Gavaler JS, Zetti GM, Starzl TE, Van Thiel DH (1993) FK506 pre-treatment is associated with reduced levels of tumor necrosis factor and interleukin 6 following hepatic ischemia/reperfusion. J Hepatol 17:301-7
40. Sakuma S, Kato Y, Nishigaki F, Magari K, Miyata S, Ohkubo Y et al. (2001) Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. Int Immunopharmacol 1:749-57
41. Scholzen TE, Stander S, Riemann H, Brzoska T, Luger TA (2003) Modulation of cutaneous inflammation by angiotensin-converting enzyme. J Immunol 170:3866-73
42. Schreiber SL (1991) Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283-7
43. Schuller E, Oppel T, Bornhovd E, Wetzel S, Wollenberg A (2004) Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol 114:137-43
44. Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU (2004) Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol 114:887-95
45. Steele JA, Choi C, Kwong PC (2005) Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol 53:713-6
46. Sugiyama M, Funauchi M, Yamagata T, Nozaki Y, Yoo BS, Ikoma S et al. (2004) Predominant inhibition of Th1 cytokines in New Zealand black/white F1 mice treated with FK506. Scand J Rheumatol 33:108-14
47. Tan J, Langley R (2004) Safety and efficacy of tacrolimus ointment 0.1% (Protopic) in atopic dermatitis: a Canadian open-label multicenter study. J Cutan Med Surg 8:213-9
48. Toubi E, Shoenfeld Y (2004) The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 37:457-64
49. Yellin MJ, Thienel U (2000) T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules. Curr Rheumatol Rep 2:24-31